会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 간암을 진단하기 위한 마커인 LCN2, MIDKINE 및TFPI, 그를 포함하는 키트 및 상기 마커를 이용한 간암예측 방법
    • LCN2,MIDKINE和TFPI,用于诊断肝细胞癌的标记物,包含其的试剂盒和使用标记物预测肝细胞癌的方法
    • KR1020070099313A
    • 2007-10-09
    • KR1020060030606
    • 2006-04-04
    • 한국원자력의학원
    • 이기호김상범윤미용박명진한철주정숙향
    • C12Q1/68
    • C12Q1/6886C12Q1/6837C12Q2600/158
    • A marker for diagnosing hepatocellular carcinoma comprising at least one polynucleotide is provided to show different expression pattern between hepatocellular carcinoma and non-tumor liver tissue, thereby being utilized for studying the tumor formation of the hepatocellular carcinoma and providing presumptions based on detailed information about tumor inhibition, detoxication and lipid metabolism during the progress of the hepatocellular carcinoma. A marker for diagnosing hepatocellular carcinoma from blood of patients suffering from it comprises at least one polynucleotide selected from the group consisting of NM_005564 (LCN2; lipocalin 2(oncogene 24p3)); NM_002391 (MIDKINE; neurite growth-promoting factor 2, transcript variant 3); NM_001012333 (MIDKINE; neurite growth-promoting factor 2, transcript variant 2); NM_001012334 (MIDKINE; neurite growth-promoting factor 2, transcript variant 1); and NM_006287 (TFPI; tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)). A kit or a micro-array for diagnosing hepatocellular carcinoma comprises the markers. A method for predicting hepatocellular carcinoma comprises the steps of: (a) measuring the expression level of at least one of the polynucleotide; and (b) comparing the measured expression level with that of a normal cell.
    • 提供用于诊断包含至少一种多核苷酸的肝细胞癌的标志物以显示肝细胞癌与非肿瘤肝组织之间的不同表达模式,从而用于研究肝细胞癌的肿瘤形成,并基于关于肿瘤抑制的详细信息提供假设 ,肝细胞癌进展期的解毒和脂质代谢。 用于从患有其的患者的血液诊断肝细胞癌的标志物包含至少一种选自NM_005564(LCN2;脂笼蛋白2(致癌基因24p3))的多核苷酸; NM_002391(MIDKINE;神经突生长促进因子2,转录物变体3); NM_001012333(MIDKINE;神经突生长促进因子2,转录物变体2); NM_001012334(MIDKINE;神经突生长促进因子2,转录物变体1); 和NM_006287(TFPI;组织因子途径抑制剂(脂蛋白相关的凝血抑制剂))。 用于诊断肝细胞癌的试剂盒或微阵列包括标记物。 一种预测肝细胞癌的方法包括以下步骤:(a)测量至少一种多核苷酸的表达水平; 和(b)将测量的表达水平与正常细胞的表达水平进行比较。
    • 8. 发明公开
    • 간암을 진단하기 위한 마커인 HLA-DMA, CD24 및SDFR1, 이들을 포함하는 키트 및 상기 마커를 이용한간암 예측 방법
    • HLA-DMA,CD24和SDFR1,用于诊断肝细胞癌的标记物,包含其的试剂盒和使用标记物预测肝细胞癌的方法
    • KR1020070099312A
    • 2007-10-09
    • KR1020060030605
    • 2006-04-04
    • 한국원자력의학원
    • 이기호김부여윤미용최동욱김상범함용호이은주
    • G01N33/574G01N33/576G01N33/53
    • A HLA-DMA, CD24 AND SDFR1 are provided to show different expression pattern between hepatocellular carcinoma and non-tumor liver tissue, thereby being utilized for studying the tumor formation of the hepatocellular carcinoma and contributing to diagnose the hepatocellular carcinoma at an early stage. A marker for diagnosing hepatocellular carcinoma comprises at least one polynucleotide selected from the group consisting of NM_006120(HLA-DMA; major histocompatibility complex, class II, DM alpha), NM_013230(CD24; small cell lung carcinoma cluster 4 antigen) and NM_012428 (SDFR1; stromal cell derived factor receptor 1). A kit for diagnosing hepatocellular carcinoma comprises the marker and a probe complementary to the polynucleotide. A method for predicting hepatocellular carcinoma comprises the steps of: (a) measuring the expression level of the polynucleotide; and (b) comparing the measured expression level with that of a normal cell.
    • 提供HLA-DMA,CD24和SDFR1以显示肝细胞癌与非肿瘤肝组织之间的不同表达模式,从而用于研究肝细胞癌的肿瘤形成并有助于早期诊断肝细胞癌。 用于诊断肝细胞癌的标志物包括至少一种选自NM_006120(HLA-DMA;主要组织相容性复合物,II类,DMα),NM_013230(CD24;小细胞肺癌簇4抗原)和NM_012428(SDFR1)的多核苷酸 ;基质细胞衍生因子受体1)。 用于诊断肝细胞癌的试剂盒包括与多核苷酸互补的标记物和探针。 一种预测肝细胞癌的方法包括以下步骤:(a)测量多核苷酸的表达水平; 和(b)将测量的表达水平与正常细胞的表达水平进行比较。